Novartis to open ‘new chapter’ of CVD treatment with NHS collaboration

Novartis to open ‘new chapter’ of CVD treatment with NHS collaboration
Credit: Shutterstock.com/ Sebastian Kaulitzki

Novartis aims to work alongside NHS England to tackle the burden of cardiovascular disease (CVD) in the UK.

Announcing its intentions, Novartis said the current proposal is to create a pioneering collaboration that brings together three projects that aim to tackle the healthcare challenge of CVD, whilst also providing increased opportunities for UK life science sector development.

The current Memorandums of Understanding (MOUs), which form the basis of the collaboration, were negotiated and signed by The Medicines Company prior to its acquisition by Novartis.

The first proposal, upon regulatory approval and the National Institute for Health and Care Excellence (NICE) assessment, would be to provide inclisiran to secondary prevention ASCVD patients through a population-level agreement.

Inclisiran is currently in Phase III development for secondary prevention patients with expected European Medicines Agency (EMA) regulatory filing in Q1 2020.

Providing inclisiran to this high-risk population could make a significant contribution towards meeting the NHS long-term commitment to preventing 150,000 cardiovascular deaths over 10 years.

The second proposal is to explore a large-scale clinical trial to evaluate the use of inclisiran to patients at very high risk of having their first cardiac event (primary prevention).

The final proposal includes the creation of an industry and academic consortium to look at manufacturing synergies that could improve the efficiency and scale at which the UK can manufacture oligonucleotide medicines – such as inclisiran.

Novartis has a unique opportunity with inclisiran to open up a new chapter in the treatment of cardiovascular disease, the world’s leading cause of mortality and disability,” said Vas Narasimhan, CEO of Novartis.

“We’re confident that innovative approaches like this will enable us to accelerate access timelines, deliver on our broader commitment to generating leading scientific evidence, and ensure continuous improvement in manufacturing efficiency and optimisation.”